PHLDA1 expression in ulcerative colitis: A potential role in the management of dysplasia

Orita,Fukuichiro; Ishikawa,Toshiaki; Ishiguro,Megumi; Okazaki,Satoshi; Kikuchi,Akifumi; Yamauchi,Shinichi; Matsuyama,Takatoshi; Tokunaga,Masanori; Uetake,Hiroyuki; Kinugasa,Yusuke

doi:10.3892/mco.2021.2354

PHLDA1 expression in ulcerative colitis: A potential role in the management of dysplasia

Authors:
- Fukuichiro Orita
- Toshiaki Ishikawa
- Megumi Ishiguro
- Satoshi Okazaki
- Akifumi Kikuchi
- Shinichi Yamauchi
- Takatoshi Matsuyama
- Masanori Tokunaga
- Hiroyuki Uetake
- Yusuke Kinugasa
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Bunkyo‑ku, Tokyo 113‑8519, Japan, Department of Specialized Surgeries, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Bunkyo‑ku, Tokyo 113‑8519, Japan, Department of Translational Oncology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Bunkyo‑ku, Tokyo 113‑8519, Japan
Published online on: July 19, 2021 https://doi.org/10.3892/mco.2021.2354
Article Number: 192
Copyright: © Orita et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pleckstrin homology‑like domain, family A, member 1 (PHLDA1) is a protein involved in cell proliferation, adhesion and migration in colon cancer. In normal large intestinal mucosa, this protein is expressed only in the crypts. By contrast, its expression in adenomas and cancers of the large intestine is spread throughout the glandular ducts, and it has been reported that PHLDA1 may be involved in the process of carcinogenesis. PHLDA1 may also be involved in the pathogenesis of ulcerative colitis (UC). The expression levels of PHLDA1 in tissues from patients with UC were analyzed using immunohistochemistry, and its relationship with the development of UC‑associated colorectal cancer (UC‑CRC) was examined. Overall, tissue samples from 143 lesions (90 colitis lesions, 39 dysplastic lesions and 14 UC‑CRC lesions) were prepared from excised specimens of 49 patients with UC who underwent surgery in Tokyo Medical and Dental University Hospital between January 2004 and December 2017. Subsequently, immunostaining for PHLDA1 was performed. PHLDA1 expression was evaluated in UC‑CRC and dysplastic tissues within the entire lesion area on the slide and in colitis over the area of the accompanying duct. The cytoplasmic staining intensity was classified into four levels, and the expression score (0‑2 points) was calculated. The median PHLDA1 expression score was 0.295 for colitis, 0.607 for dysplasia and 0.865 for UC‑CRC. The dysplasia expression score was significantly higher than the colitis score (P<0.001), while the UC‑CRC expression score was significantly higher than the dysplasia score (P=0.003). The expression levels of PHLDA1 in UC cases were higher in colitis, followed by dysplasia and UC‑CRC, which suggested that this protein may be involved in the carcinogenesis of UC‑CRC. In addition, PHLDA1 immunostaining may help in the diagnosis of dysplasia, which is a type of precancerous lesion.

View Figures

View References

1	Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW and Kaplan GG: Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterol. 142:46–54. 2012.PubMed/NCBI View Article : Google Scholar
2	Jess T, LoftusEV Jr, Velayos FS, Harmsen WS, Zinsmeister AR, Smyrk TC, Tremaine WJ, Melton LJ 3rd, Munkholm P and Sandborn WJ: Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: A population-based study from olmsted county, Minnesota. Inflamm Bowel Dis. 12:669–676. 2006.PubMed/NCBI View Article : Google Scholar
3	Chen R, Lai LA, Brentnall TA and Pan S: Biomarker for colitis-associated colorectal cancer. World J Gastroenterol. 22:7882–7891. 2016.PubMed/NCBI View Article : Google Scholar
4	Watanabe T, Konishi T, Kishimoto J, Kotake K, Muto T and Sugihara K: Japanese Society for Cancer of the Colon and Rectum. Ulcerative colitis-associated colorectal cancer shows a poorer survival than sporadic cancer: A nationwide Japanese study. Inflamm Bowel Dis. 17:802–808. 2011.PubMed/NCBI View Article : Google Scholar
5	DeRoche TC, Xiao SY and Liu X: Histological evaluation in ulcerative colitis. Gastroenterol Rep (Oxf). 2:178–192. 2014.PubMed/NCBI View Article : Google Scholar
6	Okamoto R and Watanabe M: Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease. J Gastroenterol. 51:11–21. 2016.PubMed/NCBI View Article : Google Scholar
7	Triantafillidis JK, Nasioulas G and Kosmidis PA: Colorectal cancer and inflammatory bowel disease: Epidemiology, risk factors, mechanisms of development and prevention strategies. Anticancer Res. 29:2727–2737. 2009.PubMed/NCBI
8	Vogelstein B, Fearson ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM and Bos JL: Genetic alterations during colorectal-tumor development. N Engl J Med. 319:525–532. 1988.PubMed/NCBI View Article : Google Scholar
9	Ullmam TA and Itzkowitz SH: Intestinal inflammation and cancer. Gastroenterology. 140:1807–1816. 2011.PubMed/NCBI View Article : Google Scholar
10	Takahashi H, Ishikawa T, Ishiguro M, Okazaki S, Mogushi K, Kobayashi H, Iida S, Mizushima H, Tanaka H, Uetake H and Sugihara K: Prognostic significance of Traf2- and Nck- interacting kinase (TNIK) in colorectal cancer. BMC Cancer. 15(794)2015.PubMed/NCBI View Article : Google Scholar
11	Hanaoka M, Ishikawa T, Ishiguro M, Tokura M, Yamauchi S, Kikuchi A, Uetake H, Yasuno M and Kawano T: Expression of ATF6 as a marker of pre-cancerous atypical change in ulcerative colitis-associated colorectal cancer. A potential role in the management of dysplasia. J Gastroenterol. 53:631–641. 2018.PubMed/NCBI View Article : Google Scholar
12	Sakthianandeswaren A, Christie M, D'Andreti C, Tsui C, Jorissen RN, Li S, Fleming NI, Gibbs P, Lipton L, Malaterre J, et al: PHLDA1 expression marks the putative epithelial stem cells and contributes to intestinal tumorigenesis. Cancer Res. 71:3709–3719. 2011.PubMed/NCBI View Article : Google Scholar
13	Khamas A, Ishikawa T, Shimokawa K, Mogushi K, Iida S, Ishiguro M, Mizushima H, Tanaka H, Uetake H and Sugihara K: Screening for epigenetically masked genes in colorectal cancer using 5-Aza-2'-deoxycytidine, microarray and gene expression profile. Cancer Genomics Proteomics. 9:67–75. 2012.PubMed/NCBI
14	Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S and Reed JC: Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol. 148:1567–1576. 1996.PubMed/NCBI
15	Shigaki K, Mitomi H, Fujimori T, Ichikawa K, Tomita S, Imura J, Fujii S, Itabashi M, Kameoka S, Sahara R and Takenoshita S: Immunohistochemical analysis of chromogranin A and p53 expressions in ulcerative colitis-associated neoplasia: Neuroendocrine differentiation as an early event in the colitis-neoplasia sequence. Hum Pathol. 44:2393–2399. 2013.PubMed/NCBI View Article : Google Scholar
16	Lemmon MA and Ferguson KM: Signal-dependent membrane targeting by pleckstrin homology (PH) domains. Biochem J. 15:1–18. 2000.PubMed/NCBI
17	Scheffzek K and Welti S: Pleckstrin homology (PH) like domains - versatile modules in protein-protein interaction platforms. FEBS Lett. 586:2662–2673. 2012.PubMed/NCBI View Article : Google Scholar
18	Hinz T, Flindt S, Marx A, Janssen O and Kabelitz D: Inhibition of protein synthesis by the T cell receptor-inducible human TDAG51 gene product. Cell Signal. 13:345–352. 2001.PubMed/NCBI View Article : Google Scholar
19	Neef R, Kuske MA, Pröls E and Johnson JP: Identification of the human PHLDA1/TDAG51 gene: Down-regulation in metastatic melanoma contributes to apoptosis resistance and growth deregulation. Cancer Res. 62:5920–5929. 2002.PubMed/NCBI
20	Nagai MA, Fregnani JH, Netto MM, Brentani MM and Soares FA: Down-regulation of PHLDA1 gene expression is associated with breast cancer progression. Breast Cancer Res Treat. 106:49–56. 2007.PubMed/NCBI View Article : Google Scholar
21	Zhao P, Lu Y and Liu L: Correlation of decreased expression of PHLDA1 protein with malignant phenotype of gastric adenocarcinoma. Int J Clin Exp Pathol. 8:5230–5235. 2015.PubMed/NCBI
22	Marchiori AC, Casolari DA and Nagai MA: Transcriptional up-regulation of PHLDA1 by 17beta-estradiol in MCF-7 breast cancer cells. Braz J Med Biol Res. 41:579–582. 2008.PubMed/NCBI View Article : Google Scholar
23	Toyoshima Y, Karas M, Yakar S, Dupont J, Helman L and LeRoith D: TDAG51 mediates the effects of insulin-like growth factor I (IGF-I) on cell survival. J Biol Chem. 279:25898–25904. 2004.PubMed/NCBI View Article : Google Scholar
24	Hossain GS, van Thienen JV, Werstuck GH, Zhou J, Sood SK, Dickhout JG, de Koning AB, Tang D, Wu D, Falk E, et al: TDAG51 is induced by homocysteine, promotes detachment-mediated programmed cell death, and contributes to the cevelopment of atherosclerosis in hyperhomocysteinemia. J Biol Chem. 278:30317–3027. 2003.PubMed/NCBI View Article : Google Scholar
25	Gomes I, Xiong W, Miki T and Rosner MR: A proline- and glutamine-rich protein promotes apoptosis in neuronal cells. J Neurochem. 73:612–622. 1999.PubMed/NCBI View Article : Google Scholar
26	Ren L, Mendoza A, Zhu J, Briggs JW, Halsey C, Hong ES, Burkett SS, Morrow J, Lizardo MM, Osborne T, et al: Characterization of the metastatic phenotype of a panel of established osteosarcoma cells. Oncotarget. 6:29469–29481. 2015.PubMed/NCBI View Article : Google Scholar
27	Murata T, Sato T, Kamoda T, Moriyama H, Kumazawa Y and Hanada N: Differential susceptibility to hydrogen sulfide-induced apoptosis between PHLDA1-overexpressing oral cancer cell lines and oral keratinocytes: Role of PHLDA1 as an apoptosis suppressor. Exp Cell Res. 320:247–257. 2014.PubMed/NCBI View Article : Google Scholar
28	Coutinho-Camillo CM, Lourenço SV, Nonogaki S, Vartanian JG, Nagai MA, Kowalski LP and Soares FA: Expression of PAR-4 and PHLDA1 is prognostic for overall and disease-free survival in oral squamous cell carcinomas. Virchows Arch. 463:31–39. 2013.PubMed/NCBI View Article : Google Scholar
29	Taylor HW, Boyle M, Smith SC, Bustin S and Williams NS: Expression of p53 in colorectal cancer and dysplasia complicating ulcerative colitis. Br J Surg. 80:442–444. 1993.PubMed/NCBI View Article : Google Scholar